Very low-dose, slow infusion thrombolysis offers equal efficacy with fewer complications for prosthetic heart valve thrombosis, with the optimal strategy depending on NYHA class and thrombus burden.
No takes yet. Share an insight, caveat, or question.
May inform thrombolysis protocols in developing countries; leaves open need for randomized confirmation.
Shanmugam Krishnan (2016) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: